Launch LNZ100 commercially
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 May 2024
- Due
- 31 Dec 2025
- Delivered
- August 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“commercial launch as early as the second half of 2025”
What we found
Evidence strength A What the grades mean
LENZ Therapeutics successfully launched LNZ100, rebranded as VIZZ, in August 2025, which falls within the second half of 2025 as committed.
-
A LENZ Therapeutics, Inc. 10-K filed 2026-03-24
“In July 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44%, formerly known as LNZ100, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, and we launched VIZZ commercially in the U.S. in August 2025.” ✓ confirmed on the page
Market reaction: the shares moved -17.2% against the S&P 500 over the three sessions around the disclosure (23 Mar 2026 to 26 Mar 2026). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- LNZ100 commercial launch
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: if approved
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you LENZ Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-LENZ-003365 · Corrections policy